Afraxis Inc.
This article was originally published in Start Up
Executive Summary
Afraxis Inc. is developing p21-activated kinase (PAK) inhibitors, initially for Fragile X syndrome, a genetic condition involving changes in the X chromosome that can lead to cognitive impairment and autism-like behaviors. The start-up thinks treatment of this orphan indication may be a gateway to developing PAK inhibitors for closely related conditions, such as autism and other central nervous system disorders like Alzheimer's disease and schizophrenia.
You may also be interested in...
Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases
Biotech believes that inactivation of p21-activated kinase may address underlying cause of Fragile X syndrome.
Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases
Biotech believes that inactivation of p21-activated kinase may address underlying cause of Fragile X syndrome.
Start-Up Previews (05/2011)
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Rare Disease Research: Where Compassion Meets Commerce," features profiles of Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical. Plus these Start-Ups Across Health Care: AirXpanders, Arterion, CortiCare and Sirius Implantable Systems.